BMS CA052-002

Gastrointestinal tumors, Thoracic tumors
Pancreatic cancer, Non-small cell lung cancer (NSCLC), Small cell lung carcinoma
other systemic therapies
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with advanced solid tumors.
The objective of this study is to evaluate the safety, tolerability and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with advanced solid tumors.